Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Skyrizi® (risankizumab-rzaa) – New indication, new formulation approval
June 17, 2022 - AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of moderately to severely active Crohn's disease in adults.
